Helix BioPharma Corp. (TSX: “HBP”) (OTC PINK: HBPCD) (FRANKFURT: HBP0), (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced financial results for the 2024 fiscal year ended July 31, 2024.
HELIX BIOPHARMA CORP. ANNOUNCES FISCAL 2024 YEAR-END RESULTS